VX 973
Alternative Names: VX-973Latest Information Update: 14 May 2024
At a glance
- Originator Vertex Pharmaceuticals
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pain
Most Recent Events
- 04 Apr 2024 Vertex Pharmaceuticals completes a phase I trial safety, pharmacokinetics and pharmacodynamics study in healthy subjects in United Kingdom (PO) (NCT05866055)
- 10 May 2023 Phase-I clinical trials in Pain (In volunteers) in United Kingdom (PO) (NCT05866055)